Attendees will leave this panel with a deeper understanding of the current hemp and CBD legislation and proposed legislative solutions to current regulatory and legal challenges facing the hemp and hemp-derived cannabinoid industries. Panelists will do a deep dive into current legislative proposals, as well as approaches for the 2023 Farm Bill.
Pathways to Ending Federal Prohibition: An Overview of Descheduling & Rescheduling. In 2022, President Biden directed his administration to conduct a review of the status of cannabis under the Controlled Substances Act. This session examines the review process for descheduling and rescheduling and their potential impacts.
Interstate Commerce in Theory: Raich, the Dormant Commerce Clause, and How Challenges to Social Equity Programs Could Impact Interstate Cannabis Commerce. From the Supreme Court's decision in Raich v. Gonzales to recent challenges regarding state-level importing and exporting restrictions, the Constitution's Commerce Clause has played a critical role in shaping the legal cannabis industry. Our panel of legal experts will dive deep into the precedential cases and discuss recent dormant Commerce Clause challenges to the constitutionality of social equity programs nationwide.
Interstate Commerce in Statehouses and the Courts: What Will Ultimately Bring About the Onset of Interstate Sales? At least four states have seen legislative action involving ways that interstate commerce can be triggered prior to full federal legalization, namely California, Oregon, New Jersey, and blank. This panel will explore the potential triggers that could unlock interstate sales, as well as how the lack of movement at the federal level factors into states' decision-making and operators' risks.
Interstate Commerce in Practice: What will Interstate commerce actually look like, and how will it be regulated? Assuming interstate commerce will commence before federal legalization, this session will probe the nuances of the federal government's posture toward state-regulated interstate sales will impact how products can effectively move from state to state. Presenters will discuss the practical challenges for regulators and operators in establishing an efficient and well-regulated interstate market.
Risky Business: Managing Risk Within a Cannabis Company. From insurance to human resources to employment to governance, an effective risk management policy can save money, prevent liability and put your cannabis company in a position for success. These experts will explore all the aspects of effective risk management within a cannabis company.
Here Comes the Money: Banking and Payment Processing in the Cannabis Industry. Banking and payment processing has long been one of the most misunderstood aspects of operating within the cannabis industry. This panel of experts will explore the current state of banking and payments in cannabis and how to utilize these services legally.
In this course, attendees will examine the interconnectedness of social equity initiatives and basic legal principles (i.e. justice, equity, etc.) This program will encourage diversity of thought, give cannabis attorneys more to consider when advising diverse populations and ask participants to walk a mile in a social equity applicant's shoes. Attendees will leave this course with a deeper understanding (and appreciation) of why social equity programs exist, including their role in undoing the harms of cannabis prohibition, how they serve diverse clients and promote equal access to justice, and why social equity programs are necessary.
Panelists will explore the current state of cannabis legalization in various regions throughout the Americas and highlight emerging markets with high growth potential. Attendees will leave this panel with a deeper understanding of the current state and future potential of emerging cannabis markets in the Americas, as well as insights and strategies for success in these exciting and rapidly evolving markets.
Medical Cannabis: Overview of Emerging Legal Issues and their Impact on the International Market. The international panel of experts will notably discuss the differences in regulations between medical cannabis and pharmaceutical cannabis, how IP is becoming an essential topic with pharmaceutical cannabis medicines, and how it could also impact medical cannabis in the short run.